

Syndicated Report: Access Impact of Manufacturers' 340B Restrictions

From MMIT's sister company, The Dedham Group



Why This Matters


Manufacturers increasingly have been implementing restrictions on covered entities' contract pharmacy use in an effort to prevent diversion and duplicate discounts, safeguard program integrity and promote transparency. Given variability in manufacturer policies and impact on covered entity revenue, it is critical for manufacturers to understand account response strategy and willingness to implement access restrictions on impacted and portfolio products.

Contract Pharmacy Restrictions

21 manufacturers have implemented contract pharmacy restrictions, with most manufacturers expanding to increase the scope of their restrictions, introducing variability in policy components and exemptions offered.

Contract Pharmacy Restriction Policy Dynamics

(N=21 Manufacturers, % Manufacturers)



Data last updated June 1, 2023


Covered Entity Contract Pharmacy Restrictions

Covered entities demonstrate variability in willingness to share data with manufacturers, with key drivers being legal philosophies, potential downstream reimbursement impact, and ability to absorb revenue losses.

Covered Entity Contract Pharmacy Restriction Response Likelihood

Contract Pharmacy Restriction Response Likelihood


(N=25 Accounts, Avg. Rating, 1=Unlikely, 7=Highly Likely)



Claims Data Sharing Prevalence

(N=25 Accounts, % Accounts)

Do Not Plan to Share (52%) | Currently Sharing (36%) | Under Discussion (12%)



Data last updated June 1, 2023

Key Topics Covered

- 340B Drug Pricing Program overview and trends
- Contract pharmacy restriction impact on covered entity revenue and operations
- Covered entity response willingness, precedent and execution methodologies.
- Orphan drug exclusion impact on non-Disproportionate Share Hospital covered entities and response levers
- Contract pharmacy restriction policy dynamics
- Mistaken 340B pricing blocks, stakeholders and access impact
- Voluntary "340B-like" discount removal for orphan designated drugs
- Covered entity preferencing precedent and capabilities

Connect with MMIT today to download the full Syndicated Report.

CONNECT WITH US